---
document_datetime: 2026-01-07 12:46:41
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/lunsumio-epar-all-authorised-presentations_en.pdf
document_name: lunsumio-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9920789
conversion_datetime: 2026-01-10 11:33:54.578722
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|---------------------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/22/1649/001 | Lunsumio          | 1 mg       | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 1 ml (1 mg/mL)            | 1 vial      |
| EU/1/22/1649/002 | Lunsumio          | 30 mg      | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 30 ml (1 mg/mL)           | 1 vial      |
| EU/1/22/1649/003 | Lunsumio          | 5 mg       | Solution for injection                | Subcutaneous use          | vial (glass)          | 0.5 ml (10 mg/mL)         | 1 vial      |
| EU/1/22/1649/004 | Lunsumio          | 45 mg      | Solution for                          | Subcutaneous use          | vial (glass)          | 1 ml (45 mg/mL)           | 1 vial      |

injection